ITRI vs SENS vs DXCM vs REZI vs ABT

For growth investors, Senseonics Holdings, Inc.

(SENS) is the stronger pick with 56. 9% revenue growth year-over-year, versus -3. 0% for Itron, Inc. (ITRI). Abbott Laboratories (ABT) offers the better valuation at 11. 0x trailing P/E (15. 4x forward), making it the more compelling value choice. Analysts rate Senseonics Holdings, Inc. (SENS) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Abbott Laboratories (ABT) is the cheapest at 11.

0x versus DexCom, Inc. at 29. 0x. On forward P/E, Resideo Technologies, Inc. is actually cheaper at 12. 9x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Abbott Laboratories wins at 0. 51x versus DexCom, Inc. 's 2. 24x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Resideo Technologies, Inc.

(REZI) delivered a total return of +39. 1%, compared to -86. 0% for Senseonics Holdings, Inc. (SENS). Over 10 years, the gap is even starker: DXCM returned +288. 3% versus SENS's -92. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Abbott Laboratories (ABT) is the lower-risk stock at 0.

22β versus Resideo Technologies, Inc. 's 2. 24β — meaning REZI is approximately 936% more volatile than ABT relative to the S&P 500. On balance sheet safety, Abbott Laboratories (ABT) carries a lower debt/equity ratio of 32% versus 109% for Resideo Technologies, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Senseonics Holdings, Inc.

(SENS) is pulling ahead at 56. 9% versus -3. 0% for Itron, Inc. (ITRI). On earnings-per-share growth, the picture is similar: Abbott Laboratories grew EPS 133. 6% year-over-year, compared to -718. 0% for Resideo Technologies, Inc.. Over a 3-year CAGR, SENS leads at 29. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Abbott Laboratories (ABT) is the more profitable company, earning 31.

9% net margin versus -196. 0% for Senseonics Holdings, Inc. — meaning it keeps 31. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DXCM leads at 19. 6% versus -193. 8% for SENS. At the gross margin level — before operating expenses — DXCM leads at 60. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Abbott Laboratories (ABT) is the more undervalued stock at a PEG of 0. 51x versus DexCom, Inc. 's 2. 24x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Resideo Technologies, Inc. (REZI) trades at 12. 9x forward P/E versus 23. 5x for DexCom, Inc. — 10. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SENS: 78. 9% to $9. 00.

In this comparison, ABT (2.

6% yield), REZI (0. 6% yield) pay a dividend. ITRI, SENS, DXCM do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Abbott Laboratories (ABT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

22), 2. 6% yield, +166. 6% 10Y return). Senseonics Holdings, Inc. (SENS) carries a higher beta of 2. 06 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABT: +166. 6%, SENS: -92. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ITRI (Technology) and SENS (Healthcare) and DXCM (Healthcare) and REZI (Industrials) and ABT (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ITRI is a small-cap deep-value stock; SENS is a small-cap high-growth stock; DXCM is a mid-cap high-growth stock; REZI is a small-cap quality compounder stock; ABT is a mid-cap deep-value stock. REZI, ABT pay a dividend while ITRI, SENS, DXCM do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.